Manipulation of Mitofusin2/Ras interaction as a therapy for acute ischemic kidney injury by Vemula, Pradheep
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Manipulation of Mitofusin2/Ras
interaction as a therapy for acute
ischemic kidney injury
https://hdl.handle.net/2144/15346
Boston University
 BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
MANIPULATION OF MITOFUSIN2/RAS INTERACTION AS A 
 
THERAPY FOR ACUTE ISCHEMIC KIDNEY INJURY 
 
 
 
 
by 
 
 
 
 
PRADHEEP VEMULA 
 
B.S., Johns Hopkins University, 2011 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2014  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 by 
 Pradheep Vemula 
 All rights reserved  
 Approved by 
 
 
First Reader ___________________________________________________ 
 Steven C. Borkan, M.D. 
 Associate Professor of Medicine 
 
 
Second Reader ___________________________________________________ 
 Andrea Havasi, M.D. 
 Assistant Professor of Medicine 
 
 
 
 iv 
MANIPULATION OF THE MITOFUSIN2/RAS INTERACTION AS A 
THERAPEUTIC AVENUE TO TREAT ACUTE KIDNEY INJURY 
PRADHEEP VEMULA 
ABSTRACT 
 Mitofusin 2 (MFN2), an outer mitochondrial membrane protein expressed 
in virtually all human tissues, is a multi-faceted protein known to affect 
mitochondrial morphology, metabolism, tethering, and movement as well as 
overall cell cycle progression. Most intriguing among its characteristics is its 
ability to bind to Ras and Raf, upstream effectors in the MAPK/ERK pathway. 
Conditional knockout (cKO) of renal proximal tubule MFN2 in vivo  showed a 
post-ischemic protective effect. While the two day survival of control mice was 
only 28%, an unexpected 86% of the MFN2 cKO mice were alive at two days 
post-ischemia. This is likely explained by MFN2's ability to bind and sequester 
Ras at baseline. Because the MFN2 deficient mice did not sequester as much 
Ras, renal proximal tubule cells were able to proliferate at a greater rate and 
restore organ function more quickly. Immunoprecipitation studies confirm a 
strong interaction between Ras and MFN2 in resting cells but a weaker one 
immediately following ischemic insult, even in cells replete with MFN2. These 
results suggest that blocking the MFN2-Ras interaction may be a novel method 
to  treat acute kidney injury. A small peptide mimicking Ras to block MFN2 could 
be feasible. This should grant ischemic tissue an increased propensity  to 
 v 
regenerate healthy cells while leaving non-ischemic tissue completely unaffected. 
Such a therapeutic agent would be novel in the treatment of acute kidney injury 
and may have uses in other tissues as well due to MFN2's widespread 
expression profile. 
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Introduction 
 
Recovery of Organ Function 
  One of the hallmarks of healthy cells and tissue is the ability to respond to 
stimuli by healing.  Some tissues, such as the epidermis or the lining of the 
gastrointestinal tract, have a high rate of turnover that facilitates healing in 
response to injury (Barker, 2014). In contrast, the liver does not normally have a 
high cellular turnover rate but is nonetheless recover organ function by vastly 
increasing proliferation in response to injury (Fausto, Campbell, & Riehle, 2006). 
Cardiac tissue, long thought to be completely incapable of regeneration, houses 
a population of stem cells that can generate new cardiomyocytes (Bergmann et 
al., 2009). These prior studies suggest that proliferation is critical to the recovery 
of cell and organ function after an insult. Studying this response may lead to 
valuable insight for next generation treatment options for critically ill patients.  
  
Kidney Failure 
 One area in need of such new therapies is in the treatment of kidney 
failures. In 2009, the latest year for which there is data, there were a total of 
571,414 patients with end stage renal disease (ESRD) in the United States of 
which only 172,553 had working transplanted kidneys; the remaining patients 
were supported by hemodialysis (HD) or peritoneal dialysis (PD). This is 
concerning because the 5-year survival rate for any type of dialysis compared to 
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a transplant is 35.5 percent versus 85.5 percent. Overall, 90,118 patients afflicted 
with ESRD died in 2009. In addition to ESRD, there were a further 23,052 
hospitalizations that included a diagnosis of acute kidney injury (Kidney diseases 
statistics for the united states - national kidney and urologic diseases information 
clearinghouse.).  
 Unsurprisingly,  a functioning kidney greatly enhances patients' lifespan. 
Unfortunately, no current treatment option is directly able to promote kidney 
healing. Treatment options are limited to kidney transplantation or symptomatic 
treatment using renal replacement therapy (RRT) if intrinsic kidney function is not 
sufficient to support life (Acute kidney injury treatment & management.). Dialysis 
carries with it an increased risk of complications such as cardiovascular disease, 
infection, and cancers. Not only does dialysis portend a drastically reduced long-
term prognosis, it is also financially taxing. In 2009 in the United States, annual 
dialysis costs per patient exceeded $80,000 USD (Kidney diseases statistics for 
the united states - national kidney and urologic diseases information 
clearinghouse.). Thus kidney injury desperately needs new treatments that 
promote recovery of kidney function. 
 
Synthetic Organs 
 One promising area of research is synthetic organs and tissue 
engineering. Increasing knowledge of fetal development, embryonic stem cells, 
and in the idea of induced pluripotent cells has invigorated this field by 
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suggesting that entire organs can be mass produced in a lab and then 
transplanted into patients. If this is done with the patient's own stem cells, it may 
revolutionize organ transplants. However this field is in its infancy and faces 
many dangers and many technological obstacles. Although some cells including 
cardiomyocytes are capable of contraction in a petri dish, achieving a three 
dimensional organ is immensely challenging.   
 
Mitofusin 2 
  In the aftermath of an injury, many choreographed pathways respond in a 
synergistic manner to promote healing and tissue viability. These pathways 
include apoptosis and cell proliferation. Interestingly, Mitofusin 2 (MFN2), a 
mitochondrial integral membrane protein potentially regulates both of these 
responses. It was first discovered and named 'hyperplasia suppressor gene' 
(HSG) for its anti-proliferative role (K. Chen et al., 2004). It was then renamed 
MFN2 due to its role in modulating mitochondrial morphology by promoting 
organelle fusion.  
 It is now established that MFN2 is an essential gene; mice with MFN2 
knockout are not viable. These mice develop markedly deficient placentas in 
utero. In vitro studies have established that depletion of MFN2 causes a drastic 
change in morphology from elongated to punctate mitochondria (Gall et al., 
2012). The transition to punctate form increases the susceptibility of the cell to 
apoptosis. Recent studies suggest that MFN2's powerful anti-proliferative effect 
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is actually independent of its effects on mitochondrial morphology and apoptosis. 
MFN2 binds to both Ras and Raf, thereby inhibiting MAPK and ERK, a pathway 
critical for regulating cell proliferation (K. H. Chen et al., 2014). Inhibition of 
MAPK/ERK causes cell cycle arrest, precluding cell proliferation. Due to its 
important role in both apoptosis and cell proliferation at baseline, MFN2 may be a 
key player in the post-injury cellular recovery phase (Baddour, Sousounis, & 
Tsonis, 2012). However, the role of MFN2 in renal cell proliferation after acute 
kidney injury is not presently known.  
 Inhibition of MFN2-Ras/Raf interaction is therefore a promising route to 
developing a new class of drugs that may be able to actively induce replication of 
healthy renal cells within the damaged kidney.  
 
Current Study 
 Kidney disease is a significant burden both on patient quality of life as well 
as the medical system and lacks a current treatment. In this thesis, we will 
analyze the literature for known information on MFN2. We will discuss its roles in 
mitochondrial morphology as well as in regulating proliferation via its effect on the 
Ras and MAPK/ERK pathway. We propose to interfere with MFN2 by developing 
a "mimotope", a small peptide that mimics a larger protein. It is also our goal to 
provide evidence from the literature to support the idea that such a mimotope will 
actually have the intended effect of promoting cellular proliferation after an 
ischemic renal insult. We will also discuss the feasibility of therapeutic drug 
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development including drug delivery mechanisms and potential hazards. In short, 
we propose a drug to block MFN2 in order to enhance the ability of damaged 
tissues to regenerate and recover function. Our focus will be on the kidney and 
kidney proximal tubule cells in particular, a primary target for ischemia, a 
common cause of acute kidney injury (AKI). 
 
Published Data 
 
 MFN2  
 MFN2 is a large molecular weight dynamin-related protein located on the 
outer mitochondrial membrane of mammalian cells that is essential for normal 
mitochondrial fusion. It is a 757 residue protein with a U-shaped C-terminal 
region that contains two transmembrane regions that anchor it to the outer 
mitochondrial membrane. Its cytoplasmic ends include a GTPase domain and 
binding sites for Ras, Raf, and Bax. Ras and Raf are involved in cell proliferation 
whereas Bax is the quintessential pro-apoptotic member of the B-cell lymphoma 
2 (BCL2) family. The C-terminal GTPase and the U-shaped anchor region are 
shown in figure 1. Heptad repeats 1 and 2 (HR1 and HR2 respectively) likely 
form coiled-coil structures.  
 Numerous studies have shown that MFN2 and the closely related MFN1 
are both required for mitochondrial fusion (De Brito & Scorrano, 2008). These 
two proteins have a high degree of identity (63%) and share overlapping 
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functionality with some exceptions. Figure 2 illustrates the  clustal alignment of 
MFN1 and MFN2. Compared to MFN1, MFN2 has an extended N-terminal end 
as well as decreased homology at a proposed Raf binding site (in the area of 
amino acids 77-90) (K. Chen et al., 2004; K. H. Chen et al., 2014; De Brito & 
Scorrano, 2008). Over-expression of MFN1 in MFN2 deficient cells partially 
restores minimal mitochondrial fusion whereas over-expression of MFN2 in 
MFN1 deficient cells does not. The key difference between the two, however, is 
MFN2's involvement in a variety of cellular processes (e.g., proliferation) that are 
distinct from mitochondrial morphology (Zorzano, Liesa, Sebastián, Segalés, & 
Palacín, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 (Adapted from 
Chen Lab, Caltech.edu): 
MFN2 
Schematic showing the 
cytosolic GTPase domain of 
MFN2 as well as two 
heptad repeats (HR1 and 
HR2). MFN2 is an integral 
membrane protein and has 
two transmembrane 
domains (TM), shown here 
in yellow, that anchor it to 
the outer mitochondrial 
membrane. 
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Figure 2 (adapted from (De Brito & Scorrano, 2008)): Clustal 
Alignment of MFN1 and MFN2 
The Primary sequence of MFN2 aligned with that of MFN1. Black 
indicates identical residues and grey indicates similar residues. Note the 
N-terminal extension of MFN2 as well as decreased homology around 
residues 77-90. 
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MFN2: Endoplasmic Reticulum Tethering 
 MFN2 also anchors mitochondria to the endoplasmic reticulum (ER). The 
ER normally has several distinct regions: the nuclear membrane, the smooth ER 
(SER), and the rough ER (RER). As a whole, the ER has a tubular structure that 
extends far away from the nucleus and throughout the cell. However, MFN2-
depleted cells lose some of this highly ordered structure. Additionally, knockdown 
of MFN2 hampers the transfer of calcium ions from the ER to the mitochondria. 
This is of special concern in the calcium-dependent phospholipase C signaling 
pathway. Upon binding of a G-protein coupled receptor (GPCR) at the plasma 
membrane to its ligand, phospholipase C is activated. In turn, phospholipase C 
cleaves phosphatidylinositol 4,5-bisphosphate (PIP2), a minor component of the 
plasma membrane, into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 
(IP3). IP3 then interfaces with ion channels on the ER to increase cytosolic 
calcium ions. Ca2+ acts as a second messenger to elicit a variety of responses in 
the cell. One of its targets is the mitochondria. The mitochondrial Ca2+  
concentration modulates the rate of cellular respiration as well as the cell cycle. 
As shown in figure 3, excessive  mitochondrial Ca2+ influx is dangerous by 
reducing the mitochondrial membrane potential. Dissipation of the mitochondrial 
membrane potential is a potent activator of apoptosis and promotes pore 
formation in the outer mitochondrial membrane that allows cytochrome c to 
escape into the cytosol. This stimulates apoptosis by activating the initiator 
caspases to form the apoptosome (Knox et al., 2004; Kristensen, 1994). It is 
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plausible, therefore, that MFN2 knockdown both interferes with apoptosis and 
promotes renal cell survival. Although this is a plausible hypothesis, it has not 
been shown to be true either in vivo or in vitro.  
  
Figure 3 (Adapted from (Mattson & Chan, 2003)): Apoptosis 
After binding of a death signal (a), Cytochrome C leaves the mitochondria (b), it 
facilitates Ca2+ release from ER (c), cytosolic Ca2+ increases (d), all 
mitochondria import more Ca2+, causing more cytochrome C release (e), and 
finally, formation of the apoptosome (f).  
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Mitochondrial Morphology Alters Apoptosis 
 Mouse kidney proximal tubule cells lacking MFN2 exhibit marked inability 
to fuse mitochondria in vitro resulting in numerous punctate organelles. However 
this dramatic change in mitochondrial morphology does not seem to affect 
cellular viability or organelle function at baseline (Gall et al., 2012).  ATP levels 
within renal cells, as well as their turnover, remained unchanged and the 
mitochondria preserved their oxidative reserve capacity. However, after ATP 
depletion, a well established in vitro model of ischemic stress, renal cells with 
MFN2 deficiency responded differently from wild type cells.  ATP depletion is 
achieved by placing a cell culture in a complete growth medium devoid of 
glucose but with a metabolic inhibitor that interferes with the electron transport 
chain (ETC). Rotenone, a complex I inhibitor, is often used because of its 
efficacy as well as the ability of added heptanoic acid to bypass the rotenone-
induced roadblock at complex I (Wang et al., 2010). This model not only provides 
quick and effective block of ETC but also prompt and nearly full recovery of 
mitochondrial aerobic function at a specified point. 
 Although MFN2 knockout had little detectable effect on mouse kidney 
proximal tubule cells at baseline in vitro, the results were drastically different 
under conditions of ATP depletion. Compared to control, MFN2 depleted cells 
had 80% more apoptosis as measured by Hoechst dye. Hoechst 
characteristically stains DNA in apoptotic cells. As shown in figure 4, 
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Figure 4 (adapted 
from(Gall et al., 
2012)): MFN2 
Knockout Increases 
Susceptibility to 
Apoptosis 
 
A. Bax, a pro-apoptotic 
protein, increases in 
the mitochondrial 
fraction in MFN2- ATP 
depleted cells. 
 
B. Cytosolic fractions of 
cytochrome C and AIF, 
both apoptosis 
inducers, are elevated 
in MFN- ATP depleted 
cells. 
 
C. Densitometric 
analysis of A and B. 
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both cytochrome c and apoptosis inducing factor (AIF) were elevated in the 
cytoplasm of MFN2 depleted cells. Bax, a pro-apoptotic protein, also 
accumulated to a greater extent in mitochondria of MFN2 deficient renal cells. 
(Gall et al., 2012; Wei, Dong, Franklin, & Dong, 2007). In non-renal cells several 
prior studies have suggested that MFN2 deficiency alters mitochondrial 
morphology and predisposes cells to apoptosis in response to stress (Cho, Choi, 
Cho, Kim, & Sun, 2013).  
 Given that MFN2-knockout mice are not viable into adulthood, a more 
elegant model is required to investigate the effects of MFN2 depletion in vivo. 
One such model depends on mice bred with loxP sites on either side of the 
MFN2 gene ("floxed"). The Cre recombinase is then able to cut any DNA 
between the loxP sites and eliminate it from the genome of that cell as well as 
any daughter cells. In order to control Cre expression in the kidney, it is placed 
under the control of an inducible KAP2 promoter. KAP2 is reportedly a highly 
specific promoter that is active in kidney proximal tubule cells and only induced 
when exposed to testosterone (Li, Zhou, Davis, Xu, & Sigmund, 2008). Figure 5 
shows the effectiveness of this model. In this diagram, F1F0 ATPase, a protein 
that localizes to mitochondria, is tagged with green fluorescent protein (GFP) and 
Cre is tagged with a blue fluorescent marker. The red stain is tomato red and 
indicates that these cells lack the Cre recombinase. In Cre plus (blue) cells, the 
green mitochondria are noticeably punctate whereas normal mitochondrial 
morphology is present in Cre minus (red) cells. This supports the hypothesis that 
testosterone induced Kap2
which then eliminates the floxed MFN2 loci
result is a highly specific subset of proximal tubule cells 
deficiency (Gall et al., 2012)
 When these mice were exposed to
MFN2 conditional knockout mice had a survival rate of 86% two days
ischemia whereas the control group had a comparatively dismal 28% 
rate 
 
 
 
Figure 5 (unpublished
KAP2-Testosterone and Cre Recombinase
F1F0 ATPase is tagged with GFP and localizes to the mitochondria. Difference in 
mitochondrial morphology between Cre
depresses MFN2. Cre is tagged with a blue fluorescent marker. 
 
 promoter activates synthesis of the Cre recombinase 
 within proximal tubule cells
that 
.  
 transient bilateral renal ischemia
, from Borkan SC, Boston University): MFN2 cKO with 
 
- and Cre+ suggests the presence of Cre 
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 (unpublished data, from Borkan SC, Boston University). This difference in animal 
survival strongly suggests that proximal tubule MFN2 deficiency either promotes 
renal cell proliferation, inhibits apoptosis, or both. 
 Admittedly, testosterone might predispose to ischemic renal damage 
(Park, Kim, Ahn, Bonventre, & Bonventre, 2004). In the above stud, exogenous 
testosterone was required to adequately stimulate Kap2 Cre expression in the 
proximal tubule. Although both control and MFN2 deficient mice received 
identical testosterone exposure, this hormone could potentially exaggerate the 
disparity in survival between the control and experimental groups. Development 
of an alternative, and inducible proximal tubule specific promoter could avoid this 
potential confounder.   
 Despite this potential limitation, this experiment lends support to the 
hypothesis that acute kidney injury and resulting kidney failure is partly mediated 
by proximal tubule cells. This has been presumed for decades even in the 
absence of experimental evidence (Nakhoul & Batuman, 2011). In this study, 
MFN2 was eliminated from only the proximal tubule cells and the kidneys were 
otherwise normal in both the control and experimental groups. The same 
ischemia that killed 72% of the control mice was only sufficient to kill 14% of the 
experimental mice lacking MFN2 in the proximal tubule cells. This suggests that 
proximal tubule cells account for the stark difference in animal survival.  
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MFN2 and Ras/Raf 
 What explains this profound difference in animal survival after renal 
ischemia in MFN2 deficiency mice? Increased MFN2 causes cell cycle arrest by 
increasing the levels of p21 and p27, and decreased levels of phosphorylated 
Rb, (figure 5). Both p21 and p27 are cyclin dependent kinase (Cdk) inhibitors that 
arrest the cell cycle at the G1 checkpoint. Rb normally inhibits progression 
through this checkpoint as well; phosphorylation inactivates Rb. Therefore, 
phosphorylation of Rb is a key requirement for a cell to enter S phase. MFN2 
over-expression decreases the concentration of phosphorylated Rb and, ergo, 
the rate of cell division (figure 6). There currently is no evidence to suggest a 
direct interaction between MFN2 and p21, p27, or Rb. However, MFN2 is clearly 
able to bind and inhibit both Raf and Ras, essential "cogs" in the MAPK/ERK 
pathway. These two interactions also seem independent of each other. An N-
terminal domain of MFN2 harbors a p21 Ras motif (aa 77-92) that likely binds to 
Raf while the C-terminal region directly binds to Ras. Either half of the MFN2 
protein is sufficient for effective inhibition of proliferation to occur (K. Chen et al., 
2004; K. H. Chen et al., 2014).  
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MAPK/ERK Pathway  
 MFN2's ability to inhibit Ras is important because of the importance of Ras 
in the MAPK/ERK pathway. This name is an acronym derived from the generic  
names of the effector enzymes in the pathway: Mitogen-Activated Protein Kinase 
(MAPK). This family of enzymes also had an older name: Extracellular Signal-
Regulated Kinases (ERK). As a result, this pathway is often called the 
MAPK/ERK pathway (McCubrey et al., 2007).    
 The MAPK/ERK pathway is a well-characterized signal cascade that is 
essential for a variety of cellular responses, including cell division. Classically, an 
extracellular growth factor, such as epidermal growth factor (EGF), starts the 
cascade by binding to a transmembrane receptor, epidermal growth factor 
receptor (EGFR). EGFR is a receptor tyrosine kinase (RTK); upon binding of the 
ligand, the receptor dimerizes with another EGFR. This allows the receptor dimer 
molecule to autophosphorylate at multiple tyrosine sites. These phosphorylated 
tyrosines are then recognized by proteins with SH2 domains--in this case, an 
adaptor protein named growth factor receptor-bound protein 2 (Grb2) recognizes 
activated EGFR. Grb2 is able to interact with several different proteins. With 
regards to proliferation, the interaction between an SH3 domain on Grb2 and a 
guanine exchange factor called SOS is particularly significant. SOS is the key to 
switching Ras from the "off" to the "on" state (McCubrey et al., 2007). 
 Ras is a small G protein that acts as a binary switch. In its default, or  
inactive, state Ras is bound to a guanosine diphosphate (GDP) moiety. In order 
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to become active, Ras must switch the GDP for a guanosine triphosphate (GTP). 
This does not happen spontaneously and requires the action of a guanine 
exchange factor. In this case, SOS is the protein capable of activating Ras, but 
only when the SOS itself is bound to Grb2 that is in turn bound to an activated 
RTK. Once Ras is turned on, it activates Raf, a protein kinase that 
phosphorylates and activates MEK that in turn activates mitogen-activated 
protein kinase (MAPK). MAPK, also known as ERK, is able to activate a host of 
other proteins that directly alter transcription. This includes activation of C-myc, a 
potent transcriptional activator. In addition, MAPK phosphorylates and activates 
microtubule-associated protein (MAP). Together, C-myc and MAP drive a 
reaction that leads to a profound change in transcription that strongly promotes 
cell growth and division (Goodsell, 1999; McCubrey et al., 2007).  
 Ras is an immensely powerful regulator in this pathway because it is 
upstream of several protein kinase effectors. Although the signal is detected by 
the RTK, both GRB2 and SOS are recruited, allowing Ras to initiate and amplify 
the signal. SOS is able to activate many Ras molecules. Each Ras molecule then 
activates thousands of Raf proteins. From this point, the downstream signal 
cascades is further amplified. As a result, a relatively small amplitude Ras signal 
exerts dramatic final effects on C-myc, MAP, and other transcription factors 
(figure 7). The extracellular growth factor signal is transferred intracellularly via 
the activation of Ras. Furthermore, Ras acts as a catalyst that stimulates the 
signal cascade. Included in this figure are only a few of the many downstream  
19 
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effectors of Raf. 
 
MFN2 Disorders 
 MFN2 dysfunction has classically been linked to Charcot-Marie-Tooth 
disease type 2A (CMT2A), a peripheral nervous system disorder that causes 
progressive and diffuse loss of muscle mass and sensory feedback throughout 
the body. It was initially classified as a muscular dystrophy due to the presence 
of muscle atrophy. Since 2004 however, various studies have linked the disease 
with mutations in MFN2 that compromise either its GTPase activity or its ability to 
bind nucleotides. Individuals with CMT2A lose the ability to transport 
mitochondria along axons distal to peripheral neuronal cell bodies. This results in 
axonal degeneration of both sensory and motor neurons. The muscles served by 
the degenerating axons then atrophy simply due to loss of innervation. The 
disease is a relatively common inherited neurological disorder and affects 
approximately 1 in 2,500 people (De Brito & Scorrano, 2008).  
 Studies since the discovery of MFN2's importance in CMT2A suggest that 
MFN2 is not only responsible for mitochondrial fusion and ER tethering but also 
for generalized tethering of mitochondria to other cell structures including 
microtubules. Therefore, MFN2 is also important for mitochondrial movement 
within a cell. Given their structural similarity, it is not surprising that MFN1 has 
also been shown to perform a similar function. In vitro neurons with MFN1 
knockout exhibit random motion of mitochondria throughout the cell and no 
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obvious anterograde or retrograde transport of the organelles along axons. 
Knockdown of MFN2 in MFN1 replete cells shows only a partial but significant 
decrease in the ability to transport mitochondria. However, no form of CMT has 
been associated with MFN1 mutation possibly due to its lethality (De Brito & 
Scorrano, 2008).  
 Obesity and type 2 diabetes mellitus have also been linked with MFN2 
dysfunction. Unlike CMT2A, it is unlikely that MFN2 dysfunction is a direct cause 
of either of these disorders but the changes in MFN2 expression and function in 
response to obesity and type 2 diabetes mellitus may help perpetuate these 
diseases. Indeed, many factors that alter cellular metabolism especially 
glycolysis and aerobic cellular respiration seem to affect expression of MFN2. It 
is possible that this change in metabolic activity is in part regulated by altered 
MFN2 expression. Figure 8 presents evidence supporting the hypothesis that 
knockdown of MFN2 alone depresses the rate of glucose oxidation and 
decreases mitochondrial membrane potential. The experiment was done in 
MFN2 deficient L6E9 rat cells by infection with adenovirus possessing the 
antisense MFN2 gene. Control groups were infected with adenovirus containing 
only β-galactosidase. Once transcribed, the antisense MFN2 mRNA hybridizes 
with native, sense MFN2 mRNA and silences the gene via the RNA interference 
(RISC) pathway (Bach et al., 2003; De Brito & Scorrano, 2008).   
 Obesity and type 2 diabetes mellitus are both linked to a decrease in 
MFN2 expression whereas activities such as exercise and weight loss have been 
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shown to increase expression of MFN2. Insulin also increases expression of 
MFN2 and up-regulates mitochondrial expansion and division, perhaps through 
MFN2-mediated signaling (De Brito & Scorrano, 2008).  
  
 
 
 
 
 MFN2's role as a regulator of metabolism is strengthened by evidence that 
suggests MFN2 up-regulates oxidative phosphorylation (Pich et al., 2005). MFN2 
deficiency depresses the expression of complexes I, II, II, and V whereas over-
expression of MFN2 induced increased expression of I, IV, and V. The 
suppression of complexes I, II, III, and V as a result of MFN2 knockdown is 
shown in figure 9. The fact that obese rats showed identical knockdowns of 
complexes I, II, III, and V in their skeletal muscle cells suggested that this MFN2 
effect is indeed relevant and physiological (Pich et al., 2005). 
 
Figure 8 (adapted from (Bach et al., 2003)): MFN2 Mediated Glucose Oxidation and 
Membrane Potential Changes 
Shown in white and grey are controls; glucose oxidation rate and membrane potential 
remain normal in uninfected cells and cells infected with adenovirus containing β-
galactosidase. The effect of MFN2 knockdown is shown in black (AS). The asterisks indicate 
statistically significant results. 
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Figure 9 adapted from (Pich et al., 2005): MFN2 Induced Changes in Protein 
Expression and Activity 
A. MFN2 knockdown to about 40% of baseline results in decreased expression of 
complexes I, II, III, and V of the oxidative phosphorylation pathway. 
B. Decreased activity of complexes I and III with MFN2 knockdown. 
Asterisks indicate statistically significant results. 
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Discussion 
 
MFN2 as a Therapeutic Target 
 In the aftermath of tissue injury, one of two treatment pathways is 
conceivable from a biochemical standpoint. One can either inhibit the rate of cell 
apoptosis or accelerate the rate of cellular proliferation. Using drugs with anti-
apoptotic and proliferative properties to treat ischemic tissue injury is not a novel 
idea as it has been attempted in the kidney (Patel et al., 2004) and heart (Parsa 
et al., 2003) using high levels of recombinant human erythropoietin (EPO). A 
significant improvement in tissue function in the short term was observed in both 
the kidney and the heart by manipulating anti-apoptotic and proliferative 
mechanisms (Parsa et al., 2003; Patel et al., 2004). A major disadvantage of this 
avenue of treatment is an accompanying long-term development of chronic 
fibrosis, likely due to EPO's fibrin-dependent wound healing responses (Haroon, 
Amin, Jiang, & Arcasoy, 2003).  While this may be beneficial in cardiac tissue in 
restoring structural integrity to the organ, it is counterproductive in the kidney 
(Haroon et al., 2003; Meran & Steadman, 2011).  
 Unlike EPO, MFN2 does not directly promote either apoptosis or cell 
proliferation. In fact,  MFN2 is a roadblock for proliferative and apoptotic signals. 
As evidenced in both in vitro and in vivo studies, MFN2 knockout in proximal 
tubule cells does not substantially change renal function in the absence of ATP-
depletion or ischemia. As such, it can be thought of as a stress response 
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mediator. Simply removing the roadblock it presents does not directly activate 
programmed cell death or cellular division unlike EPO that affects cells in the 
absence of other growth or death signals (Witthuhn et al., 1993).  
 This propensity of MFN2 to remain "neutral" in response to ischemic injury 
makes it alluring as a drug target. In theory, this would allow a maneuver or drug 
that interferes with MFN2 to have minimal untoward effects. Only the cells 
damaged by the injury would respond to MFN2 manipulation. Interestingly, global 
knockout of MFN2 was lethal to mice even in the absence of overt defects or 
organ injury other than placental dysfunction. Further research is needed to 
determine whether MFN2 is a potential candidate for therapeutic intervention. 
 
MFN2 and Apoptosis 
 Evaluating MFN2's precise role in apoptosis is challenging. There is 
evidence to suggest that MFN2's ability to fuse mitochondria and maintain their 
filamentous structure increases their resistance to Bax-mediated apoptosis (Gall 
et al., 2012). At least in theory, inhibiting MFN2's ER-tethering function could also 
decrease apoptosis by reducing the availability of intra-mitochondrial calcium 
ions to cause mitochondrial membrane injury (Mattson & Chan, 2003). 
 Although it is tempting to alter MFN2 to decrease apoptosis to prevent or 
treat clinical ischemia, several problems exist. Firstly, apoptosis is not universally 
unwanted in damaged tissue; rather, proper levels of apoptosis are required to 
destroy dysfunctional and irreversibly damaged cells (Programmed cell death 
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(apoptosis) - molecular biology of the cell - NCBI bookshelf.). This provides 
space for new, functional cells and ensures that limited nutrients are used by 
healthy rather than damaged cells. However, the threshold at which anti-
apoptotic therapy becomes counterproductive is unclear. MFN2 manipulation 
needs to be mild or brief enough to allow irreparably damaged cells to undergo 
apoptosis but spare cells that have normal, or close to normal, function.   
 Accurately estimating apoptosis is also a formidable challenge. In vitro 
studies generally use measures of cell viability to infer apoptosis rather than 
direct measurement. This is due to the stochastic nature of apoptosis; at any 
given moment, only a few cells will be apoptotic. Attempts to directly count 
apoptotic cells is confounded by the tendency of healthy cells to phagocytose 
and degrade apoptotic ones. Since it is not feasible at present to continually 
monitor apoptotic cells, current methods underestimate this form of cell death 
(ref). One measure often used in studies is the MTT assay. MTT, (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, is a yellow tetrazolium dye 
that is reduced in living cells to purple formazan crystals. This reaction requires 
NAD(P)H-dependent oxidoreductase enzymes that are functional only in live 
cells. A typical experiment exposes confluent plates of cells to a standardized 
insult, such as ATP-depletion before allowing the cells to recover in normal 
growth medium. To minimize the confounding effect of cell proliferation on 
viability, the medium is then supplemented for a few hours with the MTT dye. The 
dye is converted to formazan that is detected via spectroscopic analysis. The 
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rate of conversion of MTT to formazan is roughly proportional to the quantity of 
viable cells. Another issue is the dependency of this method on the metabolic 
activity of mitochondria responsible for converting the MTT; a more active 
organelle is likely able to generate more formazan than a less active one. Since 
the shortest human cell cycle time is approximately 9 hours in intestinal crypt 
cells, the MTT assay predominantly measures cell viability and is a generally 
accepted method (Twentyman & Luscombe, 1987). 
  Studies in vivo  have a similar problem and tend to use histological 
appearance to attempt to quantify apoptosis. As mentioned before, the stochastic 
nature of apoptosis limits the histological quantification at a single or even a few 
time points. The inability to meticulously catalogue apoptosis limits the 
conclusions that a study can make about drugs that alter apoptosis.   
 Manipulating MFN2 is undeniably challenging. Although MFN2 deficiency 
increases apoptosis in vitro (Gall et al., 2012), MFN2 over-expression can be 
problematic. MFN2 over-expression directly causes mitochondrial clustering, 
decreased inner membrane potential, and loss of cytochrome C to the cytoplasm 
(Huang, Yu, & Yoon, 2007). Thus the timing and degree of MFN2 manipulation 
appear to be critical.  
 
Cell Proliferation 
 Whereas MFN2's influence on apoptosis is complex, its role in cellular 
proliferation is clear. For at least a decade, dysfunction of MFN2 has been shown 
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to contribute to proliferative diseases as disparate as atherosclerosis and 
malignant neoplasms (K. Chen et al., 2004; WenJiong, GuoHua, Tao, & Bing, 
2009). Exploiting this dysfunction in a controlled manner may help damaged, 
non-malignant, tissues to more rapidly recover function. 
 As mentioned before, MFN2 interacts with Ras and Raf. Levels of MFN2 
inversely correlate with the activation of ERK1/2 in a cell free assay (Shen et al., 
2007)(unpublished data from Borkan SC, Boston University). Furthermore, 
immunoprecipitation studies suggest that Ras interacts with MFN2 at baseline in 
non-stressed cells but this interaction decreases after ATP-depletion in the 
absence of changes in the steady state content of either MFN2 or Ras 
(unpublished, see figure 10). This data is sufficient to suggest a simple model for 
how MFN2 controls cell proliferation. At baseline when proliferation is not 
necessary, MFN2 binds and sequesters Ras and Raf, limiting proliferative 
signals. The advent of cellular injury causes some as yet unknown change to 
MFN2 that allows release of Ras and presumably of Raf as well. Crucially, these 
molecules are not automatically in the "on" state-- in vitro studies of MFN2 
knockout cells have shown that function and proliferation rates are unchanged 
prior to ATP-depletion. This supports the idea that MFN2's release of these 
molecules does not in itself signal proliferation but rather prepares the cellular 
machinery to respond more robustly to proliferative signals. It should be noted, 
however, that MFN2 might activate Ras and Raf during the process of release. 
However, it appears that the absence of MFN2 or interference with its interaction 
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with Ras and Raf allows these molecules to be activated far more efficiently. This 
makes sense from a tissue, organ, and organism level. When irreparably 
damaged cells need to be destroyed, capable cells would be needed to rapidly 
replace dead cells. This rapid proliferative response is essential to the restoration 
of organ function and, ultimately, for preserving the viability of the organism.  
 MFN2's ability to bind Ras raises an interesting question. MFN2 has 
classically been described as a GTPase that promotes outer mitochondrial 
membrane fusion. MFN2 coordinates fusion in conjunction with other proteins 
including, but not limited to, mitofusin-1 (MFN1) and OPA1 (Escobar-Henriques & 
Anton, 2013). Although it has been suggested that the GTPase domain of MFN2 
is required for mitochondrial clustering prior to fusion, the details are uncertain 
(Legros, Lombes, Frachon, & Rojo, 2002; Mozdy & Shaw, 2003; Santel & Fuller, 
2001). Perhaps the MFN2 GTPase domain has a dual role. It is also known that 
MFN2 preferentially binds to GTP-bound Ras, the "on" version of the molecule 
(K. H. Chen et al., 2014). While Ras itself maintains some basal levels of 
GTPase activity to cleave a phosphate from GTP and transform it into GDP, 
there are many intracellular proteins that act as GTPases to turn off Ras in a 
quicker and more controlled manner. There exists the tantalizing possibility that 
MFN2 binds activated Ras and deactivates it via its GTPase domain. Future 
analysis of MFN2's crystal structure could illuminate this possibility. 
Nevertheless, even if the GTPase domain does not act to inactivate Ras, MFN2 
effectively suppresses the active Ras signal and prevents further activation of the 
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pathway. A drug that is able to inhibit the MFN2 interaction with Ras and/or Raf 
would be of great interest. In theory, it would have relatively few effects on 
resting cells and primarily facilitate post-ischemic tissue recovery. 
 
Mimotopes 
 One approach for interfering with this MFN2-Ras/Raf interaction is to 
employ mimotopes. These are custom-designed small peptides that specialize in 
blocking the sites of interaction between proteins. They have been made 
possible by the recent strides forward in genetic sequencing, proteomics, and 
computational biology. At its heart, the concept is simple: if molecule A interacts 
with molecule B, a small mimotope that mimics molecule B can block the binding 
site on molecule A. Molecule A would be bound by the mimotope, precluding its 
interaction with molecule B.  
 Mimotopes have a number of advantages over traditional methods of 
synthetic protein inhibition (Meloen, Puijk, & Slootstra, 2000). Past 
pharmaceutical research has often concentrated on recombinant proteins or 
small modifications of an otherwise intact biomolecule. While this has in some 
instances been fruitful, such as in recombinant insulin, this strategy often fails to 
address the issue of off-target drug effects. Proteins, especially those of 
eukaryotes, tend to have multiple domains for exquisite regulatory control and, 
perhaps, even multiple unrelated functions. Indeed MFN2 itself is one such a 
protein; its role in mitochondrial morphology seems distinct from its role in ER-
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tethering as well as its role in cell cycle-inhibition. Using modified whole proteins 
is precarious because of the potential harm off target effects could cause. 
Mimotopes, however, mimic a specific portion of a protein. This segment is 
usually in the range of 6-20 amino acids in length and implies that only one 
domain, or a fraction of one domain, is being mimicked (Meloen et al., 2000).  
 Past methods for identifying ideal mimotopes involved searching vast 
libraries of peptides and molecules either computationally or in vitro testing to 
arrive at a potentially favorable molecule. Due to the greatly increased libraries of 
protein structures in freely accessible databases such as PDB, increased 
sequence data for many organisms and proteins, and more powerful 
computational tools capable of predicting protein domains and functions, it is 
currently possible to select a protein-protein interaction and design a mimotope 
with relative ease. Such an approach holds great potential in blocking the action 
of MFN2. If it were possible to design a mimotope to mimic the binding of Ras to, 
MFN2, the result would be a MFN2 that is functional except that it is unable to 
bind or inactivate Ras, leaving Ras free to activate the MAPK/ERK pathway. A 
slight complication in that MFN2 also binds Raf. Because Raf is a downstream 
effector molecule of Ras, it may not be possible to overcome MFN2's inhibition of 
proliferation solely by interfering with Ras. If this is the case, a second mimotope 
might limit MFN2's ability to bind Raf. Importantly, MFN2 is not the sole 
intracellular binding partner of Ras and Raf. Therefore, it may be possible to 
initiate the desired MAPK/ERK response solely by interfering with MFN2/Ras 
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binding as other cellular stores of Raf may be sufficient to activate the 
MAPK/ERK pathway in response to activated Ras. Once mimotopes have been 
developed to disrupt this interaction, directed research will ascertain the 
therapeutic necessity for a mimotope directed against Raf.  
 
Ras Mimotope Design 
 The specific design of a mimotope is fairly straightforward if one of two 
pieces of data are known. Either the 3D structure of both molecules needs to be 
deduced by x-ray crystallography or a specific binding site needs to be 
established by biochemical means in order to implicate a region of the protein's 
primary sequence. In other words, either we need to know exactly how the two 
proteins look and deduce interaction sites or we need to identify the specific Ras 
region that interacts with MFN2. Unfortunately, current research on these two 
molecules cannot reliably provide either piece of information. The crystal 
structure of Ras has been known for some time; however MFN2 has yet to be 
resolved. The C-terminal half of MFN2, specifically amino acids 490-757, is 
essential for Ras binding (K. Chen et al., 2004). In addition, this portion of MFN2 
shares structural characteristics with other Ras effector molecules. Proteins in 
this family, called RASSF, often exert powerful anti-proliferative effects and act 
as tumor suppressors in a manner similar to the proposed mechanism for MFN2 
by binding GTP-bound Ras.  
 A mimotope can at most be about 20 amino acids before various factors 
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complicate its effect (Meloen et al., 2000). Serial truncation of a vast region (e.g. 
MFN2 amino acids 490-757) to a mere 20 amino acid epitope is challenging, but 
necessary in order to develop an effective inhibitor. One way to do this would be 
to create sequentially shorter deletion mutants. Using this approach, one 
molecule would represent residues 490-757, another 600-757, one 700-757, and 
so forth. Although tedious, it would facilitate a more exact determination of the 
correct interaction site. 
 The introduction of a “foreign” peptide into an organism raises the 
possibility of immune response, especially if the peptide exposure is repeated.  In 
theory, this might occur with peptides of 8 or more amino acid residues (Monzavi-
Karbassi, Cunto-Amesty, Luo, & Kieber-Emmons, 2002).  Since the proposed 
mimotopes would exceed this length, it is possible that the organism could 
become immunized against an individual peptide, limiting the number of potential 
doses or rendering it ineffective for a second or third episode of tissue renal 
injury.  It is possible that small modifications could alter it antigenicity and 
facilitate the repeated use of a closely related (but antigenically distinct) 
mimotopes.  
 Another theoretic issue yet to be addressed is whether the Ras binding 
site on MFN2 is the most ideal one. If we make a mimotope that mimics MFN2, it 
will actually recognize GTP-bound Ras. This will likely have an anti-therapeutic 
effect by mimicking MFN2's inhibition of Ras and could actually further suppress 
cellular proliferation. There is the chance that a correctly designed mimotope 
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may bind to GTP-Ras prevent it from interacting with any other GTPases that 
might inactivate it. This may be therapeutic by prolonging the growth signal. 
 Perhaps more intriguing is the identity of the Ras site that binds to MFN2-
an ideal therapeutic target. If a Ras epitope can be isolated that interacts with 
MFN2, a respective mimotope can be designed to block MFN2. This mimotope 
would block MFN2's effects without directly affecting Ras, a potent growth signal 
that integrates inputs from a variety of cellular pathways. With the mimotope 
obscuring the Ras binding site on MFN2, more Ras would be available to 
stimulate proliferation. In theory, this effect should closely resemble the effect of 
ATP depletion on MFN2-Ras interaction in renal cells. This interaction, shown in 
the immunoprecipitation results in figure 10, is strongest in resting cells prior to 
ATP depletion. After ATP depletion however, interaction between Ras and MFN2 
markedly decreases despite unchanged cellular concentrations of Ras and 
MFN2. Once the blocking effect of the Ras mimotope has been tested, it may be 
beneficial to further explore a second mimotope to block the Raf binding site on 
MFN2. If this can be achieved, MFN2 will no longer inhibit the MAPK/ERK 
pathway, enhancing cellular division and renal recovery from ischemia.  
 
Potential Off Target Effects of a Ras Mimotope 
 The proposed mimotope requires almost complete homology to the Ras 
epitope that interacts with MFN2. Although it should be possible to flank this 
sequence with residues that induce preferential interaction between the  
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mimotope and MFN2, it is quite possible that the mimotope might bind other 
proteins. Ras is a highly conserved, small protein in mice of only 189 amino acids 
that acts as a binary switch molecule. As a result, Ras does not have multiple 
binding sites where it can interact with various proteins. It has a GTP binding 
pocket, the "switch" domain, GTPase activity, and likely one or two effector sites. 
A mimotope would share homology with this effector site and therefore potentially 
bind a large subset of proteins that interact with Ras. These off target effects 
could have a wide variety of unforeseen consequences. This is partly due to the 
fact that the molecular details of the MFN2/Ras binding have not yet been 
deciphered. The proposed Ras mimotope could act as a constitutively active or 
inactive Ras molecule. Both formulations could be problematic, especially if the 
Figure 10b (unpublished, from Borkan SC, Boston University):  
Densitometric analysis of figure 10a showing the strength of the MFN2/Ras 
interaction at: baseline, 1 hour post-ATP depletion, and baseline in MFN2 depleted 
cells. 
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mimotope effect is prolonged.  
 The lesser of two evils is that the mimotope acts as a constitutively active 
Ras. This would potentially over stimulate cell-proliferation in the target tissue. 
While the threat of cancerous growth is still remote because the mimotope has a 
relatively short half-life, excessive proliferation could still endanger tissue and 
organ function. The off-target effects of the mimotope will likely depend on 
whether MFN2 binds active or inactive Ras or whether the mimotope acts as a 
constitutively active or inactive Ras molecule. Importantly, the primary goal of the 
proposed mimotope is to inactivate MFN2 rather than activate Ras. The other 
possibility is that the proposed mimotope would imitate Ras and bind to 
downstream Ras effectors but without activating them. Then the mimotope would 
effectively be a competitive inhibitor of Ras. In this scenario, the MAPK/ERK 
pathway and cellular proliferation would be selectively inactivated. 
 
GTPase Domain 
 A prominent feature of MFN2 is its GTPase domain. Early evidence 
suggests that the GTPase activity is intricately linked to the mitochondrial fusion 
and mitochondrial tethering functions of MFN2 (Maher, 2013) . But the 
observation that Ras, a small G protein, binds to MFN2 should prompt further 
research into whether MFN2 GTPase activity alters Ras activity. Ras is a 
molecular switch that is "on" when bound to GTP and "off" when bound to GDP 
(McCubrey et al., 2007). Since MFN2 not only binds to Ras but also contains a 
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GTPase domain, it is reasonable to question whether MFN2 inactivates Ras by 
accelerating the hydrolysis of GTP into GDP. If MFN2 does act as a GTPase for 
Ras, it would strengthen the argument that inactivating MFN2 is therapeutically 
beneficial for increasing cell proliferation and tissue repair.  
 Any planned manipulation of MFN2, though, should be carefully designed 
so as to spare this GTPase domain from being physiologically altered. Besides 
its role in mitochondrial fusion and tethering, it has also been implicated in 
intracellular mitochondrial movement and modulation of mitochondrial 
metabolism. As discussed earlier, the neurodegenerative disease CMT2A is 
caused by mutations in the GTPase domain and the nucleotide binding pocket of 
MFN2 (De Brito & Scorrano, 2008). Any planned manipulation should either 
leave these regions intact or utilize a drug delivery mechanism that precludes 
uptake into neurons. MFN2 also mediates a profound effect on mitochondrial and 
cellular metabolism. MFN2 is known to regulate oxidative phosphorylation, 
especially in response on hormones such as insulin or factors such as exercise 
and weight loss (De Brito & Scorrano, 2008; Pich et al., 2005). The details and 
mechanism of this action are presently unknown but it is evident that MFN2 can 
up-regulates expression of oxidative phosphorylation proteins. It may involve 
signaling through Ras or perhaps through another signaling mechanism using its 
GTPase domain. The possibility that MFN2 might regulate metabolism solely 
through fusion of mitochondria cannot be excluded. Whether the GTPase domain 
participates in the MFN2-Ras interaction or not, all these other factors suggest 
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that the activity of the GTPase domain of MFN2 is quite complex and might prove 
to be a challenging target for therapeutic intervention.  
 
Drug Delivery Mechanism 
 Delivering the proposed drug presents further challenges. On a molecular  
scale, a 20 amino acid mimotope is relatively small, but not small enough to pass 
through cell membranes with high efficiency. Fortunately, a commercially 
available and cheap method to surmount this obstacle exists. Cell penetrating 
peptides (CPPs) are short amino acid sequences that can be added to the end of 
the mimotope that enhances its ability to diffuse across the plasma membrane. 
The first CPP to be discovered was a part of the trans-activating transcriptional 
activator (Tat) protein of human immunodeficiency virus 1 (HIV-1). Since this 
discovery, many more have been identified and several have been synthesized 
based on designs found in nature. The variety of CPPs available allows tight 
control of the nature of the mimotope transport into cells. Some CPPs work by 
directly penetrating the membrane; others use transport proteins and or 
endocytosis for uptake. Once a mimotope is developed, cell delivery is highly 
unlikely to be an important obstacle (Tunnemann et al., 2006).  
 Administration of the drug, however, may prove somewhat more 
challenging. A mimotope bound to a CPP is in reality, a small peptide of at most 
25 amino acids. Such small molecules have extraordinarily low half-lives in the 
blood and are rapidly excreted by glomerular filtration. Recent research has 
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shown that the half-life of small peptides can be drastically increased by 
covalently bonding them to polyethylene glycol (PEG). On the other hand, this 
method increases the bioaccumulation of PEG and potential PEG toxicity. 
However it has been shown that an amino acid sequence of proline, alanine, and 
serine (a PAS sequence) can be added to small peptides to recreate the effect of 
PEG and extend half-lives by a factor of sixty (Schlapschy et al., 2013). These 
alterations have been shown to preserve the bioactivity of interferon, growth 
hormone, or Fab fragments of antibodies and may be effective for prolonging 
mimotope half-lives. The small peptides that this PASylation method has been 
tested on are in the 150+ amino acid size. Because mimotopes are significantly 
smaller than this, the sheer size of the PASylation may distort the desired 
mimicking effect. 
 Another issue of note is that this proposed mimotope is to treat post-
ischemic tissue injury and promote recovery. By its very nature, the area of tissue 
most in need of therapy may be an area in which blood flow required for drug 
delivery is reduced. This may necessitate the use of repeated, high doses or 
delivery to a site where drug absorption is more prolonged (e.g., intraperitoneal 
injection). 
 
Cancer Risk 
 As mentioned above, MFN2 has been implicated as a tumor suppressor 
gene. Numerous studies have linked MFN2 dysfunction to hepatocellular 
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carcinoma, gastric cancer, breast cancer, urinary bladder cancer, and many 
other tumor types (Gutschner & Diederichs, 2012; Jin et al., 2011). In these 
cases, MFN2 levels were almost universally either below normal or MFN2 was 
mutated, thereby disabling its anti-proliferative effects. This is not  surprising 
since carcinogenesis classically requires the modification of multiple genes to 
both disable tumor suppressors and to activate oncogenes, of which Ras is a 
prominent member. The observation that so many cancer cells have impaired 
MFN2 suggests that MFN2 is indeed a powerful anti-proliferative agent and an 
effective tumor suppressor protein.  
 Studies have also shown that introduction of exogenous MFN2 slows 
tumor growth. This effect was observed even in cell lines that had normal intrinsic 
expression and activity of MFN2 (Jin et al., 2011). This data reinforces reports 
that demonstrate MFN2-RAS interaction. Studies are currently underway to more 
accurately describe the binding between MFN2 and Ras as well as 
consequences of interrupting this interaction as occurs during stress and cellular 
division.  These results have garnered great excitement in using MFN2 as a 
therapeutic agent to slow the progression of cancers.  
 If MFN2 is such a powerful tool to use against cancers and if its 
dysfunction predicts a poor tumor prognosis, is it then a good idea to inhibit 
MFN2 as a therapy for ischemic tissue injury? Inhibition or deletion of MFN2 has 
not lead to any reported tumors in vivo, although this has not a primary focus of 
prior studies. The multi-hit theory of carcinogenesis posits that a single mutation 
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or failure is generally not sufficient to cause a neoplasm. A series of mutations 
and failures must precede the development of autocrine growth signals, the 
inability to recognize anti-proliferative signals or to undergo apoptosis, to become 
senescent, initiate angiogenesis, invade neighboring membranes and tissues, 
and finally to promote metastases (Gutschner & Diederichs, 2012). Fortunately, 
an effective mimotope directed against MFN2 would, in theory, satisfy only one 
or a few of these pro-cancerous conditions. 
 The duration effect of the mimotope would be expected to be transient. 
The average half-life of an intracellular protein in the human body is thought to be 
between 45 minutes and 22.5 hours (Eden et al., 2011). The median length of a 
protein in the human body is 375 amino acids--far larger than the proposed 
mimotope (Brocchieri & Karlin, 2005). Proteome-wide studies of protein 
degradation rates in budding yeast have shown a strong correlation between the 
length of a protein and its half-life (Belle, Tanay, Bitincka, Shamir, & O'Shea, 
2006). Taken together, these facts suggest that the half-life of a mimotope would 
likely be measured in hours. In fact, the mimotope half-life in the bloodstream 
might be even shorter since peptides are rapidly cleared (Meloen et al., 2000). 
Such a fleeting effect is potentially advantageous. A persistent mimotope signal 
that affects cell cycle progression could be deleterious. There is very little risk of 
development of cancer given the short term exposure time to these proposed 
mimotopes.   
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Conclusion 
 
 Regenerative medicine is by some respects one of the holy grails of 
modern medicine. Despite a rapidly advancing knowledge of basic cell 
biochemistry, relatively few therapies have been devised that take advantage of 
the body's capacity for tissue repair. A great deal of research has been done, and 
continues to be undertaken, in the field of tissue engineering and transplantation. 
Although exceedingly slow in some tissues such as the brain and heart, virtually 
all human tissues retain some inherent regenerative capability. We propose here 
that, at least for kidney and for its proximal tubule cells, a primary target of 
ischemic injury, tissue regeneration may be a viable therapeutic approach. 
  The MFN2/Ras interaction offers a tantalizing option for this purpose. It is 
ideally suited as a therapeutic target to modify cell-proliferation for a variety of 
reasons. Firstly, knockdown of MFN2 at baseline in a confluent kidney proximal 
tubule primary cell culture produces few detectable, functional changes. Although 
the mitochondria are notably punctate, aerobic function, cell survival, and kidney 
function are all unaffected (Gall et al., 2012). As such, a proposed peptide that 
would block MFN2 from interacting with Ras should not affect non-ischemic 
tissues. The preponderance of data suggests that MFN2 limits Ras activation by 
proliferative signals in healthy cells but can be readily manipulated when 
proliferation is required for  tissue repair. This very specific nature of the 
MFN2/Ras interaction is an ideal therapeutic target. In addition, the MFN2/Ras 
44 
 
interaction is not specific to kidney proximal tubule cells. MFN2 expression has 
been reported in virtually all the tissues of the body with the exception of select 
peripheral nervous tissues. This observation raises the exciting possibility that 
this may be a therapeutic target for many different types of ischemia as well as 
for ischemic acute kidney injury.   
 
Future Directions 
 
 Additional information regarding the basic biochemistry and structure of 
MFN2 would vastly assist the development of a suitable mimotope for therapeutic 
purposes. 
 
MFN2 Structure 
 While the 757 amino acid sequence of MFN2 has been known for some 
time, its precise 3-D structure remains elusive. At present, the structure of MFN2 
by high-resolution X-ray crystallography remains unsolved. Despite this obstacle, 
biochemical and bioinformatics techniques have allowed researchers to establish 
functional features within the sequence of MFN2 such as a GTPase domain, a 
transmembrane domain, nucleoside binding sites, Ras binding region, and a 
probable Raf binding site, among other features. A lack of understanding of the 
entire structure of MFN2, however, greatly impedes theoretical work on how 
MFN2 functions. For example, it has been shown that Ras can bind and inhibit 
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both Ras and Raf yet it is unknown whether the interaction between MFN2 and 
Ras/Raf are independent or biochemically related events. Although these two 
binding sites are sequentially distant from each other, MFN2 tertiary structure 
may reveal that these two binding sites are physically proximate to each other. 
Furthermore, and more relevant to our proposal, the 3-D structure of MFN2 
would greatly aid in the design of a proper mimotope to target the MFN2/Ras 
interaction. The structure of Ras has already been solved and so MFN2's 
structure would allow a better computational analysis to identify the interaction 
site on both Ras and MFN2 so that an effective mimotope that mimics Ras and 
effectively binds MFN2 and the Ras binding site can be generated.   
 
Ras Dissociation in Response to Ischemic Stress 
 The mechanism of Ras "release" by MFN2 in response to ischemic stress 
is presently unknown. However, it is clear that ATP-depletion induces a signal 
that decreases MFN2-Ras interaction. Given prior experience with ATP 
depletion, we propose that this event is mediated by phosphorylation, de-
phosphorylation, a change in nucleotide binding, or is mediated by an adaptor 
protein.  
 
MFN2/Ras Interaction in Non-Renal Tissues 
 Both MFN2 and Ras are expressed in a wide variety of human tissues. 
Studies have shown that MFN2 and Ras interact in kidney proximal tubule cells 
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and in vascular tissue (K. Chen et al., 2004) (unpublished data from Borkan SC), 
suggesting that this interaction could be present in virtually all cell types and 
tissues.  On one hand, a successful mimotope may help treat a variety of organs 
and organ systems. However there is also a danger; kidney proximal tubule cells 
do not proliferate much at baseline and therefore MFN2 depletion has little to no 
effect in the absence of ischemic injury. However other tissues, such as the lining 
of the gut and the hematopoietic system, are constantly proliferating. As a result, 
therapeutic mimotope may dangerously augment cell division at these sites. 
Careful targeting to the intended tissues could minimize or avoid this potential 
complication.   
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